{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:32:55Z","timestamp":1760189575582},"reference-count":67,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Int. J. Hematol. Oncol."],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.2217\/ijh-2017-0003","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T10:55:55Z","timestamp":1498820155000},"page":"13-24","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Current Challenges in the Management of Follicular Lymphoma"],"prefix":"10.2217","volume":"6","author":[{"given":"Maryam Sarraf","family":"Yazdy","sequence":"first","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC20007, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC20007, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12562"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07721.x"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.9.2528.bloodjournal8592528"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23958"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624288"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63186"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59806"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002197"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2332"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6546"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082412"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_2_23_1","volume-title":"The 56th American Society of Hematology","author":"Rummel MJ","year":"2014","unstructured":"Rummel MJ , MaschmeyerG, GanserAeaet al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL) \u2013 7 year updated results from the StiL NHL1 study. Presented at: The 56th American Society of Hematology. San Francsico, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_3_2_26_1","volume-title":"The 55th American Society of Hematology (ASH) Annual Meeting","author":"Salles G","year":"2013","unstructured":"Salles G , SeymourJF, FeugierPet al. Updated 6-year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Presented at: The 55th American Society of Hematology (ASH) Annual Meeting. New Orleans, LA, USA, 7\u20139 December 2013."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.7819"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)70008-0"},{"key":"e_1_3_2_29_1","volume-title":"The 56th American Society of Hematology (ASH) Annual Meeting","author":"Maurer MJ","year":"2014","unstructured":"Maurer MJ , GhesquieresH, AnsellSMet al. Event-free survival at 12 months (EFS12) from diagnosis is a robust endpoint for disease-related survival in patients with follicular lymphoma in the immunochemotherapy era. Presented at: The 56th American Society of Hematology (ASH) Annual Meeting. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_3_2_31_1","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","author":"Shi Q","year":"2016","unstructured":"Shi Q , FlowersCR, HiddemannWet al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J. Clin. Oncol.JCO2016708651 (2016) (Epub ahead of print).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4293.4293"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.132811"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"e_1_3_2_36_1","volume-title":"American Society of Clinical Oncology (ASCO) Annual Meeting","author":"Martin P","year":"2014","unstructured":"Martin P , JungSH, JohnsonJLet al. CALGB 50803 (Alliance), a Phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA, 30 May\u20133 June 2014."},{"key":"e_1_3_2_37_1","volume-title":"The 58th American Society of Hematology (ASH) Annual Meeting","author":"Kimby E","year":"2016","unstructured":"Kimby E , RondeauS, VanazziAet al. Rituximab plus lenalidomide versus rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. First analysis of survival endpoints of the randomized Phase-II trial SAKK 35\/10. Presented at: The 58th American Society of Hematology (ASH) Annual Meeting. San Diego, CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_3_2_39_1","volume-title":"The 56th American Society of Hematology (ASH) Annual Meeting","author":"Smith SM","year":"2014","unstructured":"Smith SM , PitcherB, JungSHet al. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed\/refractory B cell lymphomas: alliance A051201 and A051202. Presented at: The 56th American Society of Hematology (ASH) Annual Meeting. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633156"},{"key":"e_1_3_2_41_1","volume-title":"The 57th American Society of Hematology (ASH) Annual Meeting","author":"Fowler N","year":"2015","unstructured":"Fowler N , BoydTE, SharmanJPet al. Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma. Presented at: The 57th American Society of Hematology (ASH) Annual Meeting. Orlando, FL, USA, USA, 5 December \u2013 8 December 2015."},{"key":"e_1_3_2_42_1","volume-title":"The 56th American Society of Hematology (ASH) Annual Meeting","author":"Bartlett NL","year":"2014","unstructured":"Bartlett NL , LaPlantBR, QiJet al. Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL), preliminary results of a Phase II Consortium (P2C) trial. Presented at: The 56th American Society of Hematology (ASH) Annual Meeting. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_43_1","volume-title":"The 58th American Society of Hematology (ASH) Annual Meeting","author":"Gopal AK","year":"2016","unstructured":"Gopal AK , SchusterSJ, FowlerNet al. Ibrutinib as treatment for chemoimmunotherapy-resistant patients with follicular lymphoma: first results from the open-label, multicenter, Phase II DAWN study. Presented at: The 58th American Society of Hematology (ASH) Annual Meeting. San Diego, CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-597914"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_3_2_46_1","volume-title":"The 58th American Society of Hematology (ASH) Annual Meeting","author":"Fowler N","year":"2016","unstructured":"Fowler N , NastoupilL, de VosSet al. Ibrutinib combined with rituximab in treatment-na\u00efve patients with follicular lymphoma: arm 1 + arm 2 results from a multicenter, open-label Phase II study. Presented at: The 58th American Society of Hematology (ASH) Annual Meeting. San Diego, CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-718106"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117671"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-378323"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9718"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"e_1_3_2_53_1","volume-title":"The 58th American Society of Hematology (ASH) Annual Meeting","author":"Cheson B","year":"2016","unstructured":"Cheson B , Trn\u011bn\u00fdM, BouabdallahKet al. Obinutuzumab plus Bendamustine followed by Obinutuzumab maintenance prolongs overall survival compared with Bendamustine alone in patients with Rituximab-Refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN study. Presented at: The 58th American Society of Hematology (ASH) Annual Meeting. San Diego, CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_2_54_1","volume-title":"The 58th American Society of Hematology (ASH) Annual Meeting","author":"Marcus RE","year":"2016","unstructured":"Marcus RE , DaviesAJ, AndoKet al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized Phase III GALLIUM study. Presented at: The 58th American Society of Hematology (ASH) Annual Meeting. San Diego, CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70128-2"},{"key":"e_1_3_2_56_1","volume-title":"The 56th American Society of Hematology (ASH) Annual Meeting","author":"Morschhauser F","year":"2014","unstructured":"Morschhauser F , FlinnI, AdvaniRH. Updated results of a Phase II randomized study (ROMULUS) of Polatuzumab vedotin or Pinatuzumab vedotin plus Rituximab in patients with relapsed\/refractory non-Hodgkin lymphoma. Presented at: The 56th American Society of Hematology (ASH) Annual Meeting. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_57_1","volume-title":"The 58th American Society of Hematology (ASH) Annual Meeting","author":"Herrera A","year":"2016","unstructured":"Herrera A , MatasarM, AssoulineSet al. Polatuzumab vedotin combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in patients with relapsed or refractory (R\/R) follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), preliminary results of a Phase Ib\/II dose-escalation study. Presented at: The 58th American Society of Hematology (ASH) Annual Meeting. San Diego, CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4079"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70551-5"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1205"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7163"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw124"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13947"},{"key":"e_1_3_2_69_1","volume-title":"The 58th American Society of Hematology (ASH) Annual Meeting","author":"Chong EA","year":"2016","unstructured":"Chong EA , SvobodaJ, NastaSDet al. Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy. Presented at: The 58th American Society of Hematology (ASH) Annual Meeting. San Diego, CA, USA, 3\u20136 December 2016."}],"container-title":["International Journal of Hematologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/ijh-2017-0003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:27:20Z","timestamp":1715941640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/ijh-2017-0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.2217\/ijh-2017-0003"],"URL":"https:\/\/doi.org\/10.2217\/ijh-2017-0003","relation":{},"ISSN":["2045-1393","2045-1407"],"issn-type":[{"value":"2045-1393","type":"print"},{"value":"2045-1407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iijh20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iijh20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}